Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
David E. Griffith (Tyler, United States of America), David Griffith, Patrick Flume, Kevin Winthrop, Rachel Thomson, Dirk Wagner, Jakko Van Ingen, Liza Micioni, John P. McGinnis II, Carlos Fernandez, Gina Eagle. A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC). Eur Respir J 2015; 46: Suppl. 59, 3945

Member's Comments

No comment yet.

Related content which might interest you: A double blind randomized study of aminoglycoside infusion with combined therapy for pulmonary mycobacterium avium complex disease Source: Annual Congress 2006 - Clinical epidemiology of tuberculosis Year: 2006 Prospective study of nontuberculous mycobacteria (NTM) isolates in children with cystic fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 209s Year: 2002 Retrospective observation of mycobacterium avium complex lung disease followed without treatment Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I Year: 2019 Nontuberculous mycobacteria (NTM) infections among patients who were positive for acid fast bacilli in direct specimens - the retrospective study Source: Eur Respir J 2004; 24: Suppl. 48, 191s Year: 2004 Efficacy and safety of kanamycin addition in patients with drug-refractory mycobacterium avium complex lung disease Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Feasibility study for a randomized controlled trial of pseudomonas aeruginosa eradication treatment in patients with bronchiectasis Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Treatment of pulmonary NTM infection: can it be done? Source: Annual Congress 2007 - Nontuberculous mycobacteria (NTM): a slow-growing challenge Year: 2007 Durability of culture conversion in patients receiving Amikacin Liposome Inhalation Suspension (ALIS) for treatment-refractory Mycobacterium avium complex lung disease (MAC-LD) in the CONVERT study Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019 Positive respiratory samples with mycobacteria non tuberculous and aspergillus fumigatus: Retrospective and multicenter study Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Treatment outcomes of non tuberculous mycobacterial (NTM) pulmonary disease. Multicenter study Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection Year: 2020 Frequency of mycobacteriosis among the patients with positive cultures of nontuberculous mycobacteria (NTM) – 5 year study Source: Eur Respir J 2004; 24: Suppl. 48, 190s Year: 2004 Retrospective investigation of patients positive for glycopeptidolipid-core antibody to mycobacterium avium complex pulmonary disease Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014 A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1) Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea Source: Eur Respir J, 51 (3) 1702467; 10.1183/13993003.02467-2017 Year: 2018 Treatment outcomes of macrolide-resistant mycobacterium avium complex lung disease Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Treatment of refractory mycobacterium avium complex lung disease with a moxifloxacin-containing regimen Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response Source: Eur Respir J 2004; 23: 741-746 Year: 2004